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F ms-related tyrosine kinase 3 (FLT3)-internal tan-dem duplication (ITD) is observed in approxi-
mately 30% of adult and 15% of pediatric AML patients 
[1],  and both groups generally show poor prognosis,  
even after hematopoietic stem cell transplantation 
(HSCT) [2].  A recent study report the heterogeneity of 
prognosis in AML patients with FLT3-ITD,  but further 
details remain to be clarified [3].  We encountered a 
12-year-old female AML patient with FLT3-ITD.  
Successful complete remission was achieved after 2 con-
secutive induction chemotherapies,  ECM (etoposide,  
cytarabine and mitoxantrone) and HCEI (high-dose 
cytarabine,  etoposide and idarubicine),  following the 
Japan Pediatric Leukemia Study Group (JPLSG) AML05 
protocol [4].  After 1 more course of intensified chemo-
therapy,  the patient received HSCT from her one-locus 
mismatched sister after undergoing a busulfex (BU) and 
melphalan (L-PAM) conditioning regimen.  Relapse 
occured 4 months after HSCT,  and the same FLT3-ITD 
clone was observed.  A retrospective study revealed an 
allelic FLT3-ITD/wild type (WT) ratio of 0.0096 in the 
bone marrow sample taken prior to HSCT.  Furthermore,  
the WT1 mRNA level before HSCT did not fall below 
the cutoff point.  A second HSCT was performed from 
the patient’s human leukocyte antigen (HLA)-matched 
brother,  but the presence of FLT3-ITD remained detect-
able.  The patient died 5 months after the second HSCT.  
In this report,  we discuss the prognostic usefulness of 
minimal residual disease (MRD) of FLT3-ITD in AML 
patients.
Case Report
The patient was a 12-year-old girl who had suffered 
general fatigue for a month,  and presented with pallor 
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Acute myeloid leukemia (AML) patients with fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication 
(ITD) often have a poor prognosis,  even after hematopoietic stem cell transplantation (HSCT).  We report a 
case of AML with FLT3-ITD identified upon initial diagnosis,  who received HSCT at complete remission after 3 
consecutive chemotherapies.  However,  the patient relapsed when the same FLT3-ITD clone emerged,  and 
finally died.  Retrospective analysis revealed an allelic ratio of FLT3-ITD/wild type of 1.1 and 0.0096 upon initial 
diagnosis and before HSCT,  respectively.  The detection of any minimal residual FLT3-ITD clone before HSCT 
is useful in the treatment of AML with FLT3-ITD.
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and petechiae.  Blood tests showed a white blood cell 
count of 8.2 × 104 /µL,  with 94% myeloblasts,  a hemo-
globin level of 5.3 g/dL,  and a platelet count of 
1.2 × 104 /µL.  Bone marrow examination revealed a 
nucleated cell count of 49.9 × 104 /µL,  with 74% myelo-
blasts,  classifying the patient as subgroup M2 according 
to the French-American-British (FAB) classification.  
Blasts were positive for CD13,  CD33,  and HLA-DR,  
and negative for CD2,  CD19,  CD34,  and CD41 by flow 
cytometric analysis.  Chromosomal analysis by the 
G-banding method of bone marrow cells showed no 
abnormalities,  but molecular analysis revealed a 24 bp 
FLT3-ITD.  Induction chemotherapy was administered 
according to the JPLSG-AML05 protocol (Fig. 1) [4],  
and complete remission was achieved after the second 
course of induction therapy.  According to the protocol,  
this patient was classified into the high risk group and 
underwent allogeneic bone marrow transplantation 
from her HLA 7/8-matched sister.  Myeloablative con-
ditioning was carried out with BU and L-PAM,  and 
graft versus host disease (GVHD) prophylaxis was done 
with tacrolimus and methotrexate.  Engraftment 
occurred on Day + 19.  No acute GVHD developed.  The 
patient was discharged on Day + 71,  and tacrolimus was 
discontinued on Day + 79.  On Day + 114,  blood tests 
revealed an elevated white blood cell count of 9,770 /µL 
with 21% myeloblasts.  On Day + 119,  bone marrow 
examination revealed 83.2% myeloblasts,  and relapse of 
AML was confirmed.  The patient subsequently under-
went donor lymphocyte infusion (DLI) and high-dose 
cytarabine treatment,  but did not achieve remission.  
She proceeded to undergo a second allogeneic periph-
eral blood stem cell transplantation (SCT) from her 
HLA-matched brother using non-myeloablative condi-
tioning with gemtuzumab ozogamicin,  cytarabine,  
idarubicin,  fludarabine,  and total body irradiation 
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Fig. 1　 Clinical course of the patient.  ECM,  etoposide,  cytarabine,  mitoxantrone; HCEI,  high-dose cytarabine,  etoposide,  idarubi-
cine; HCM,  high dose cytarabine,  mitoxantrone; BU,  busulfex; L-PAM,  melphalan; Flu,  ﬂudarabine; IDA,  idarubicine; HDCA,  high-
dose cytarabine; GO,  gemtuzumab ozogamicin; LDCA,  low-dose cytarabine; ACR,  aclarubicin; CR,  complete remission; DLI,  donor 
lymphocyte infusion; SCT,  stem cell transplantation; TBI,  total body irradiation.
(TBI,  2Gy).  GVHD prophylaxis was carried out with 
cyclosporine.  Donor chimerism in the peripheral blood 
according to Y-chromosome Fluorescence in situ 
hybridization (FISH) analysis was 96.2% on Day + 14 
after the second SCT,  suggesting potential engraftment.  
However,  blasts in the peripheral blood increased rap-
idly thereafter.  After four courses of palliative chemo-
therapy,  the patient died on Day + 131 after the second 
SCT.   
Materials and Methods
Informed consent was obtained from the patient and 
her parents.  The Institutional Ethics Committee of 
Okayama University approved the genetic analysis 
(No. 2282).
MRD monitoring using FLT3-ITD by PCR. Bone 
marrow DNA from samples taken at each examined 
time point were extracted using a QIAamp DNA Blood 
Mini Kit (Qiagen,  Valencia,  CA,  USA),  following 
the manufacturer’s recommendations.  Polymerase 
chain reaction (PCR) was performed in a 25 μL 
mixture containing 100 ng gDNA,  160 μM of each 
deoxynucleotide (dNTP),  1 × PCR buffer,  2.5 mM 
MgCl2,  1 U AmpliTaq Gold DNA polymerase (Applied 
Biosystems,  Foster City,  CA,  USA),  5% dimethyl 
sulfoxide,  2 pmol of forward primer 5’-[6-FAM]- 
GCAATTTAGGTATGAAAGCCAGC-3’,  and 2 pmol 
of reverse primer 5’-gtttcttCATCTTTGTTGCT-
GTCCTTCCAC-3’,  which covered exons 14 and 15,  on 
a T100TM thermal cycler (Bio-Rad Laboratories,  
Hercules,  CA,  USA).  The PCR conditions were as fol-
lows: 94°C for 10 min,  followed by 95°C for 15 sec,  
58°C for 30 sec,  and 72°C for 30 sec,  for 35 cycles,  
and finally 72°C for 5 min.  The size and positions of the 
peaks were analyzed using an ABI 310 genetic analyzer 
(Applied Biosystems).  The allelic ratio of FLT3-ITD/
wild type (AR) was calculated by GeneScan software 
(version 3.1.2) (Applied Biosystems).  
Direct sequencing of FLT3-ITD PCR products.
PCR products were separated on a 3% agarose gel,  and 
the mutant bands were isolated and directly sequenced 
using a BigDye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems) and an ABI 310 genetic analyzer 
(Applied Biosystems).  Sequences were compared to the 
WT sequence (Accession NG_007066. 1).
WT1 mRNA expression by real time PCR and 
NUP98-NSD1 expression by RT-PCR. Bone marrow 
RNA from samples taken at each examined time point 
was extracted using an RNeasy Mini Kit (Qiagen),  fol-
lowing the manufacturer’s recommendations.  WT1 
mRNA expression was analyzed by real time PCR using 
the WT1 mRNA Assay Kit “Otsuka” and the COBAS 
Taqman 48 Analyzer (Roche,  Switzerland).
Results
A 24 bp FLT3-ITD was detected in the initial bone 
marrow (BM) sample,  and the allelic ratio (AR) was 1.1 
(Figs. 2 , 3).  MRD was detected by FLT3-ITD (AR 
0.0096) prior to the first HSCT.  The calculated MRD by 
FLT3-ITD was estimated to be less than 10-2 
(0.0096/1.1 = 0.008727).  No FLT3-ITD was detected in 
the BM samples on Day + 33 or Day + 62 after the first 
HSCT; however,  FLT3-ITD was detected at relapse on 
Day + 119 after the first HSCT.  The size of the ITD was 
the same as at initial presentation,  and the AR was 1.1. 
WT1 mRNA levels at each time point showed compara-
ble changes.  (Fig. 4).  Furthermore,  NUP98-NSD1 chi-
mera or NPM1 mutations were both negative.
Discussion
AML patients with FLT3-ITD generally have a poor 
prognosis.  The use of HSCT was recommended in the 
AML05 study; however,  HSCT has been shown to not 
improve the final clinical outcome of AML patients with 
FLT3-ITD [5].  A recent study reports the heterogeneity 
of prognosis in AML patients with FLT3-ITD [3].  
Patients with a high AR of FLT3-ITD/WT or NUP98-
NSD1 chimera have been shown to have a poor progno-
sis,  but patients with both FLT3-ITD and NPM1 gene 
mutation have been shown to have a relatively good 
prognosis [3 , 5].  In the present case,  the patient’s poor 
prognosis may have been indicated by the high AR 
(1.1).  
On the other hand,  after hematological remission,  
MRD before HSCT is reported to be an important pre-
dictor of prognosis [6].  Many AML patients with FLT3-
ITD have normal karyotypes,  and chimera such as 
MLL-AF4 are not observed; in such cases,  the assess-
ment of MRD by flow cytometry is recommended [7].  
The assessment of MRD using WT1 mRNA expression 
has also been reported to be useful [8].  Araki et al. 
examined the MRD of FLT3-ITD and report a signifi-
cant difference in the final outcome of patients with 
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MRD-positive remission (n = 76) vs.  those with MRD-
negative remission (n = 235) in 3-year relapse rate (67% 
vs.  22%) and 3-year overall survival rate (26% vs.  73%) 
[9].  The present case also showed MRD-positive remis-
sion detected by FLT3-ITD and WT1mRNA,  both,  
before HSCT and resulted in a poor prognostic out-
come.  Thus,  MRD monitoring by specific FLT3-ITD 
clone was shown to be helpful in these patients,  and 
may allow treatment improvement in patients with 
MRD after HSCT,  including the consideration of early 
withdrawal of immune-suppressive drugs or DLI.  On 
the other hand,  the first FLT3-ITD clone observed at 
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Fig. 3　 The FLT3︲ITD/WT allelic ratio (AR) over time.  The AR 
was 1.1 in the samples taken both at diagnosis and at relapse.  The 
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Fig. 4　 WT1  mRNA expression level in the bone marrow samples 
over time.  The WT1  mRNA expression was higher than the cut-oﬀ 
level prior to 1st SCT.
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WT Ref. NG_007066.1 :  … TTC TAC GTT GAT TTC AGA GAA TAT GAA TAT GAT CTC AAA TGG …
FLT3-ITD at diagnosis :  … TTC TAC GTT GAT TTC AGA GAA TAT GAA TAT GCT GAT TTC AGA GAA TAT GAA TAT GAT CTC AAA TGG …  
FLT3-ITD at relapse   :  … TTC TAC GTT GAT TTC AGA GAA TAT GAA TAT GCT GAT TTC AGA GAA TAT GAA TAT GAT CTC AAA TGG … 
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Fig. 2　 A 24 bp FLT3︲ITD was detected in both the patientʼs initial diagnostic and relapse samples.  Furthermore,  an amino acid 
change was found only in the ﬁrst ITD region (GCT>GAT,  p.Ala600Asp).
diagnosis may disappear,  or a new clone may emerge 
during the relapse phase in the some cases.  Therefore,  
careful and serial assessment for the presence of FLT3-
ITD clones is important.
In addition,  the preferred method for MRD detec-
tion based on the presence of FLT3-ITD has recently 
been shifting from PCR to next-generation sequencing 
[10 , 11].  Thus,  the assessment of FLT3-ITD detection 
method sensitivity is warranted in future studies.
In conclusion,  MRD of FLT3-ITD before HSCT 
seemed to be a predictor of poor prognosis in this AML 
patient.  Further larger-scale studies to assess the use-
fulness of this mutation as a predictor will be needed.
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